Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods.
The human reduced folate carrier (hRFC) mediates the membrane transport of reduced folates and classical anti-folates into mammalian cells. RFC is characterized by 12 transmembrane domains (TMDs), internally oriented N and C termini, and a large central linker connecting TMDs 1-6 and 7-12. By co-expression and N-hydroxysuccinimide methotrexate (Mtx) radioaffinity labeling of hRFC TMD 1-6 and TMD 7-12 half-molecules, combined with endoproteinase GluC digestion, a substrate binding domain was previously localized to within TMDs 8-12 (Witt, T. L., Stapels, S. E., and Matherly, L. H. (2004) J. Biol. Chem. 279, 46755-46763). In this report, this region was further refined to TMDs 11-12 by digestion with 2-nitro-5-thiocyanatobenzoic acid. A transportcompetent cysteine-less hRFC was used as a template to prepare single cysteine-replacement mutant constructs in which each residue from Glu-394 to Asp-420 of TMD 11 and Tyr-435 to His-457 of TMD 12 was replaced individually by a cysteine. The mutant constructs were transfected into hRFC-null HeLa cells. Most of the 50 single cysteine-substituted constructs were expressed at high levels on Western blots. With the exception of G401C hRFC, all mutants were active for Mtx transport. Treatment with sodium (2-sulfonatoethyl) methanethiosulfonate (MTSES) had no effect on hRFC activity for all of the cysteine mutants within TMD 12 and for the majority of the cysteine mutants within TMD 11. However, MTSES inhibited Mtx uptake by the T404C, A407C, T408C, T412C, F416C, I417C, V418C, and S419C mutants by 25-65%. Losses of activity by MTSES treatment for T404C, A407C, T412C, and I417C hRFCs were appreciably reversed in the presence of excess leucovorin, a hRFC substrate. Our results strongly suggest that residues within TMD 11 are likely critical structural and/or functional components of the putative hRFC transmembrane channel for anionic folate and anti-folate substrates.
Hou
Zhanjun
Z
Developmental Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA.
Stapels
Sarah E
SE
Haska
Christina L
CL
Matherly
Larry H
LH
D000595:Amino Acid Sequence; D000838:Anions; D001224:Aspartic Acid / Q000737:chemistry; D015153:Blotting, Western; D002460:Cell Line; D002462:Cell Membrane / Q000378:metabolism; D003545:Cysteine / Q000737:chemistry*; D003600:Cytosol / Q000378:metabolism; D005492:Folic Acid / Q000737:chemistry; D005973:Glutamine / Q000737:chemistry; D006367:HeLa Cells; D006639:Histidine / Q000737:chemistry; D006801:Humans; D020014:K562 Cells; D002955:Leucovorin / Q000737:chemistry; D026901:Membrane Transport Proteins / Q000737:chemistry* / Q000378:metabolism; D008698:Mesylates / Q000494:pharmacology; D008856:Microscopy, Fluorescence; D008969:Molecular Sequence Data; D016296:Mutagenesis; D009154:Mutation; D010455:Peptides / Q000737:chemistry; D011485:Protein Binding; D011487:Protein Conformation; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary; D058978:Reduced Folate Carrier Protein; D013439:Sulfhydryl Reagents / Q000494:pharmacology; D013696:Temperature; D013861:Thiocyanates / Q000494:pharmacology; D013997:Time Factors; D014162:Transfection; D014443:Tyrosine / Q000737:chemistry
D000838:Anions; D026901:Membrane Transport Proteins; D008698:Mesylates; D010455:Peptides; D058978:Reduced Folate Carrier Protein; C548699:SLC19A1 protein, human; D013439:Sulfhydryl Reagents; D013861:Thiocyanates; D005973:Glutamine; C109153:(2-sulfonatoethyl)methanethiosulfonate; D001224:Aspartic Acid; D014443:Tyrosine; D006639:Histidine; D005492:Folic Acid; D003545:Cysteine; C008658:2-nitro-5-thiocyanobenzoic acid; D002955:Leucovorin